Close Menu

Diagnostics

News and analysis on diagnostic technologies and applications.

The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.

The Toronto-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.

The Swedish firm Biovica said this and additional studies will form the basis of a US Food and Drug Administration submission for its test measuring thymidine kinase-1.

The company attributed the revenue decline in part to working capital restraints and long manufacturing lead times, which are being addressed currently.

OvaCis is a CE-IVD marked in vitro diagnostic that can be used to assess epithelial ovarian cysts.

 

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.